Wave Life Sciences
Pre-Approval PRO BETAPipeline by Phase
Therapeutic Focus
Clinical Trials (14)
Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy
Started: 12/28/2025
Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy
Started: 9/4/2019
A Phase 1 Study of WVE-007 in Adults Living With Overweight or Obesity
Started: 1/31/2025
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Started: 9/28/2021
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
Started: 7/19/2024
A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)
Started: 11/14/2023
Study of WVE-003 in Patients With Huntington's Disease
Started: 9/6/2021
Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)
Started: 6/28/2021
Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)
Started: 12/14/2022
Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
Started: 7/17/2017
Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
Started: 7/17/2017
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
Started: 9/24/2019
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
Started: 4/13/2020
Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy
Started: 1/24/2018